We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Panel of Oligonucleotide Probes and Primers Ready for Influenza Researchers

By LabMedica International staff writers
Posted on 21 Apr 2010
Molecular biologists and virologists working on the influenza virus will welcome the introduction of a new panel of oligonucleotide probes and primers that may be used to resolve the genetic signatures of a variety of influenza strains.

The panel is being marketed by Biosearch Technologies (Novato, CA, USA) and is produced under license from the developer, the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) and from F. More...
Hoffmann-La Roche (Basel, Switzerland).

The reagents – probes and primers – are intended for use in qPCR (quantitative real time polymerase chain reaction) protocols. The procedure for qPCR follows the general principle of polymerase chain reaction; its key feature is that the amplified DNA is detected as the reaction progresses in real time, compared to standard PCR, where the product of the reaction is detected at its end. Two common methods for detection of products in real-time PCR are (1) nonspecific fluorescent dyes that intercalate with any double-stranded DNA, and (2) sequence-specific DNA probes consisting of oligonucleotides that are labeled with a fluorescent reporter, which permits detection only after hybridization of the probe with its complementary DNA target.

The Biosearch Influenza A Subtyping ValuPanel Reagents comprise oligonucleotides based on the following seven signature sequences: universal strain of influenza A; influenza A H1 subtype; influenza A H3 subtype; influenza A H5a subtype; influenza A H5b subtype; universal strain of influenza B, and RNase P as a positive control.

"Over the past few years, Biosearch has developed advanced manufacturing capability and quality system management, which set us apart from traditional oligonucleotide suppliers,” said Dr. Ron Cook, president and CEO of Biosearch Technologies. "We are pleased to apply our expertise to provide these important new reagents for the detection of all major strains of influenza. We expect to augment this listing as new assays become available.”

Related Links:
Biosearch Technologies
Centers for Disease Control and Prevention
F. Hoffmann-La Roche



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.